{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-012084","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.340116+00:00","generated_at":"2026-06-19T11:12:14.820398+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Silo Pharma files provisional patent for CNS-homing peptides to treat Alzheimer's","bullets":["Filed provisional patent for CNS-homing peptides targeting Alzheimer's disease and dementia.","Peptides designed to reduce toxicity and improve therapeutic payload delivery to affected cells.","CEO Eric Weisblum cited unmet need for effective Alzheimer's treatments and targeted delivery approach.","Silo Pharma continues preclinical studies of novel therapeutics including psychedelic research."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-012084","json":"https://secwatch.observer/filing/0001213900-23-012084.json","markdown":"https://secwatch.observer/filing/0001213900-23-012084.md","text":"https://secwatch.observer/filing/0001213900-23-012084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023012084/0001213900-23-012084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023012084/ea173740-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:12:14.820398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}